芬兰关节置换登记2009至2017年6,080例初次全髋关节置换术中Tritanium髋臼杯的假体生存率
基于芬兰关节置换登记2009年1月1日至2017年12月31日的数据,比较6,080例使用Tritanium超多孔涂层髋臼杯与25,670例使用常规髋臼杯的初次全髋关节置换术。Tritanium组5年任何原因翻修生存率94.7%(95%CI 94.0%至95.4%)低于对照组96.0%(95%CI 95.7%至96.3%);>4年时段任何原因翻修风险HR为3.12(95%CI 1.82至5.35;p<0.001)。结论认为超多孔涂层Tritanium杯相比常规非骨水泥杯无优势,部分HR估计的宽置信区间可能提示精度不足,需进一步研究。
要点
- Tritanium组5年任何原因翻修生存率94.7%,低于对照组96.0%。
- >4年时段Tritanium组任何原因翻修风险高于对照组,HR 3.12(95%CI 1.82至5.35;p<0.001)。
- 髋臼杯无菌性松动翻修风险Tritanium组在0至2年(HR 3.80)和>2至4年(HR 11.2)均高于对照组。
核心结论
- 与常规非骨水泥杯相比,超多孔涂层Tritanium杯用于初次全髋关节置换术无优势。
- 部分HR估计的置信区间宽,可能提示精度不足,因此需进一步研究。
研究设计与样本
- 基于芬兰关节置换登记的人群登记研究,纳入2009年1月1日至2017年12月31日期间6,080例使用Tritanium杯的初次全髋关节置换术和25,670例使用常规杯的初次全髋关节置换术(对照组)。
- 采用Kaplan-Meier法计算生存率及95%置信区间,终点为任何原因翻修或髋臼杯无菌性松动翻修。
- 采用Cox多重回归模型评估翻修风险,评估变量包括股骨头尺寸、年龄组、受累侧、手术年份、性别、诊断和股骨柄固定方式;因比例风险假定不满足,随访时间分为0至2年、>2至4年和>4年三个时段。
主要发现
- 任何原因翻修:Tritanium组5年Kaplan-Meier生存率94.7%(95%CI 94.0%至95.4%)低于对照组96.0%(95%CI 95.7%至96.3%)。
- 任何原因翻修:>4年时段Tritanium组风险高于对照组,HR 3.12(95%CI 1.82至5.35;p<0.001)。
- 髋臼杯无菌性松动翻修:0至2年时段Tritanium组风险高于对照组,HR 3.80(95%CI 1.76至8.24;p<0.001)。
- 髋臼杯无菌性松动翻修:>2至4年时段Tritanium组风险高于对照组,HR 11.2(95%CI 3.28至38.0;p<0.001)。
关键数值与推荐
- 任何原因翻修5年生存率:Tritanium组94.7%(95%CI 94.0%至95.4%)vs 对照组96.0%(95%CI 95.7%至96.3%)。
- 任何原因翻修>4年时段:Tritanium组较对照组风险升高,HR 3.12(95%CI 1.82至5.35;p<0.001)。
- 髋臼杯无菌性松动翻修0至2年时段:Tritanium组较对照组风险升高,HR 3.80(95%CI 1.76至8.24;p<0.001)。
- 髋臼杯无菌性松动翻修>2至4年时段:Tritanium组较对照组风险升高,HR 11.2(95%CI 3.28至38.0;p<0.001)。
临床怎么用
- 作者结论认为超多孔涂层Tritanium杯用于初次全髋关节置换术相比常规非骨水泥杯无优势。
- 原文未据此给出推荐。
局限性
- 部分HR估计的置信区间宽,可能提示精度不足。
- 需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To enhance osseointegration in total hip arthroplasty (THA), ultraporous or highly porous-coated cups were introduced. Implant survival data on these new devices have been scarce. The aim of our study was to assess the survivorship of ultraporous Tritanium cups (Stryker) in a population-based register study. METHODS: In this study, we collected data on 6,080 primary THAs using a Tritanium cup and 25,670 THAs using a conventional cup (control group) from the Finnish Arthroplasty Register; these procedures were performed from January 1, 2009, to December 31, 2017. We calculated the Kaplan-Meier survival estimates with 95% confidence intervals (CIs). The end point was revision for any reason or for aseptic loosening of the cup. The revision risks were assessed with use of the Cox multiple regression model. The variables assessed in the Cox model were femoral head size, age group, involved side, operation year, sex, diagnosis, and fixation of the stem. The proportional hazards assumption of the Cox model was not fulfilled, so the follow-up time was divided into 3 time periods: 0 to 2 years, >2 to 4 years, and >4 years. RESULTS: When comparing the 2 groups with regard to revision for any reason, the 5-year Kaplan-Meier survivorship of the Tritanium group (94.7% [95% CI, 94.0% to 95.4%]) was inferior to that of the control group (96.0% [95% CI, 95.7% to 96.3%]). In the Cox regression analysis of the 2 groups for the time period of >4 years, the Tritanium group had an increased risk of revision for any reason compared with the control group (hazard ratio [HR], 3.12 [95% CI, 1.82 to 5.35]; p < 0.001). With regard to revision for aseptic loosening of the cup, the Tritanium group had an increased risk of revision compared with the control group for both 0 to 2 years (HR, 3.80 [95% CI, 1.76 to 8.24]; p < 0.001) and >2 to 4 years (HR, 11.2 [95% CI, 3.28 to 38.0]; p < 0.001). CONCLUSIONS: There was no advantage to using the ultraporous-coated Tritanium cup for primary THA compared with conventional uncemented cups. However, wide CIs for some HR estimates may point to a lack of precision. Therefore, further research on subject is needed. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
引用
- Palomäki A, Hemmilä M, Laaksonen I, et al. Implant Survival of 6,080 Tritanium Cups in Primary Total Hip Arthroplasty: Data from the Finnish Arthroplasty Register from 2009 to 2017. J Bone Joint Surg Am. 2020. PMID: 32618925. doi:10.2106/JBJS.19.00874
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。